Joseph Cappello - 19 Feb 2024 Form 4 Insider Report for GENELUX Corp (GNLX)

Role
VP, Pharmaceutical Development
Signature
/s/ Sean Ryder, Esq., Attorney-in-Fact
Issuer symbol
GNLX
Transactions as of
19 Feb 2024
Net transactions value
$0
Form type
4
Filing time
08 Jul 2024, 16:30:14 UTC
Previous filing
12 Sep 2023
Next filing
18 Dec 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GNLX Common Stock Award $0 +3,661 +64% $0.000000 9,396 19 Feb 2024 Direct F1
transaction GNLX Common Stock Award $0 +11,557 +123% $0.000000 20,953 14 Mar 2024 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs are fully vested as of February 17, 2024.
F2 Represents RSUs that are fully vested as of March 14, 2024.